Stephanie A. Schultz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie A. Schultz has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
Bruce P. Hermann
10 shared publicationsCynthia M. Carlsson
10 shared publicationsSanjay Asthana
10 shared publicationsSterling C. Johnson
10 shared publicationsCatherine L. Gallagher
9 shared publicationsMark A. Sager
9 shared publications
Latest Publications
- Open Access
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e218564
Association Between Plasma N-Terminal Tau, Cognitive Decline, and Neurodegeneration in the ADNI Cohort
Background and ObjectivesBlood-based biomarkers offer a cost-effective, minimally invasive alternative to neuroimaging and CSF biomarkers. Newly developed fluid biomarkers, including the N-terminal...
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e218564
Open AccessAssociation Between Plasma N-Terminal Tau, Cognitive Decline, and Neurodegeneration in the ADNI Cohort
Background and ObjectivesBlood-based biomarkers offer a cost-effective, minimally invasive alternative to neuroimaging and CSF biomarkers. Newly developed fluid biomarkers, including the N-terminal...
- Top Cited PapersOpen Access
- 11 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1676-1681
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
Elevated blood levels of phosphorylated tau (p-tau) are diagnostic of Alzheimer disease and are associated with the deposition of amyloid-β in the cerebral neuropil. Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. Here we analyzed p-tau in serum from four different cohorts of people with the most common types of systemic amyloidosis, transthyretin (ATTR) amyloidosis and immunoglobulin light chain (AL) amyloidosis. We found higher levels of serum p-tau181 in the AL and ATTR groups than in controls. Subsequent analyses revealed that these effects were more pronounced in the presence of polyneuropathy (PNP) and in AL compared to ATTR amyloidosis. Individuals with different forms of PNP that were not due to amyloidosis did not exhibit elevated p-tau181 levels. In cases of presymptomatic (genetic) ATTR, p-tau181 levels increased as a function of predicted years from symptom onset. Additional measurement of p-tau217 in one cohort revealed similar increases, and discriminated people with AL and those with ATTR from controls equally as well as p-tau181. These findings suggest that elevated serum p-tau levels are not specific to Alzheimer disease and may also serve as a diagnostic tool of ATTR and AL amyloidosis, with potential utility in distinguishing amyloidosis-related PNP from PNP of other etiologies.
- 11 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1676-1681
Top Cited PapersOpen AccessBlood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
Elevated blood levels of phosphorylated tau (p-tau) are diagnostic of Alzheimer disease and are associated with the deposition of amyloid-β in the cerebral neuropil. Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. Here we analyzed p-tau in serum from four different cohorts of people with the most common types of systemic amyloidosis, transthyretin (ATTR) amyloidosis and immunoglobulin light chain (AL) amyloidosis. We found higher levels of serum p-tau181 in the AL and ATTR groups than in controls. Subsequent analyses revealed that these effects were more pronounced in the presence of polyneuropathy (PNP) and in AL compared to ATTR amyloidosis. Individuals with different forms of PNP that were not due to amyloidosis did not exhibit elevated p-tau181 levels. In cases of presymptomatic (genetic) ATTR, p-tau181 levels increased as a function of predicted years from symptom onset. Additional measurement of p-tau217 in one cohort revealed similar increases, and discriminated people with AL and those with ATTR from controls equally as well as p-tau181. These findings suggest that elevated serum p-tau levels are not specific to Alzheimer disease and may also serve as a diagnostic tool of ATTR and AL amyloidosis, with potential utility in distinguishing amyloidosis-related PNP from PNP of other etiologies.
- Open Access
REM Sleep is Associated with Cognition and Biomarkers Longitudinally in Older Adults Across the Alzheimer Disease Continuum
Sleep disturbances represent a potentially modifiable risk factor for Alzheimer disease (AD). The extent to which changes in rapid eye movement (REM) sleep are related to the accumulation of AD pathology and brain tissue loss is not well understood. In the current study, ninety-four individuals 74 clinically unimpaired [CU] and 20 clinically impaired [CI]) underwent polysomnography (PSG), cognitive assessments, and neuroimaging. Cross-sectional and longitudinal models examined the associations between PSG outcomes of interest (percentage of sleep period spent in REM [%REM] and REM latency) and pre-clinical Alzheimer’s cognitive composite-5 (PACC5) scores, entorhinal tau-positron emission tomography (PET; 18F-flortaucipir), cerebral amyloid-PET (11C-Pittsburgh Compound B; PiB), AD signature cortical thickness, and hippocampal volume, after adjusting for covariates. Across CU and CI individuals, less time spent in REM sleep and prolonged REM latency were associated with poorer cognition after adjusting for age, sex, and years of education. Additionally, these factors were associated with a greater AD pathologic burden after adjusting for age and sex. Longitudinal data, spanning up to 16 years, demonstrated that the rate of change in cognition and AD biomarkers in the time preceding PSG assessment was also strongly associated with REM characteristics. Our findings highlight the potentially bidirectional relationship between the accumulation of AD pathology and the disruption of REM sleep. Future studies are needed to better understand the longitudinal relationship between sleep characteristics, AD progression, and cognitive decline, and to assess the potential of sleep-focused interventions to alter the course of AD clinical, cognitive, and pathological progression. One Sentence Summary: Cognitive and biomarker data are associated with REM sleep characteristics in unimpaired and impaired individuals cross-sectionally and over time.
Open AccessREM Sleep is Associated with Cognition and Biomarkers Longitudinally in Older Adults Across the Alzheimer Disease Continuum
Sleep disturbances represent a potentially modifiable risk factor for Alzheimer disease (AD). The extent to which changes in rapid eye movement (REM) sleep are related to the accumulation of AD pathology and brain tissue loss is not well understood. In the current study, ninety-four individuals 74 clinically unimpaired [CU] and 20 clinically impaired [CI]) underwent polysomnography (PSG), cognitive assessments, and neuroimaging. Cross-sectional and longitudinal models examined the associations between PSG outcomes of interest (percentage of sleep period spent in REM [%REM] and REM latency) and pre-clinical Alzheimer’s cognitive composite-5 (PACC5) scores, entorhinal tau-positron emission tomography (PET; 18F-flortaucipir), cerebral amyloid-PET (11C-Pittsburgh Compound B; PiB), AD signature cortical thickness, and hippocampal volume, after adjusting for covariates. Across CU and CI individuals, less time spent in REM sleep and prolonged REM latency were associated with poorer cognition after adjusting for age, sex, and years of education. Additionally, these factors were associated with a greater AD pathologic burden after adjusting for age and sex. Longitudinal data, spanning up to 16 years, demonstrated that the rate of change in cognition and AD biomarkers in the time preceding PSG assessment was also strongly associated with REM characteristics. Our findings highlight the potentially bidirectional relationship between the accumulation of AD pathology and the disruption of REM sleep. Future studies are needed to better understand the longitudinal relationship between sleep characteristics, AD progression, and cognitive decline, and to assess the potential of sleep-focused interventions to alter the course of AD clinical, cognitive, and pathological progression. One Sentence Summary: Cognitive and biomarker data are associated with REM sleep characteristics in unimpaired and impaired individuals cross-sectionally and over time.
- Open Access
- 8 January 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (1) , e71049
Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
INTRODUCTION: Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS: Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS: NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION: Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights: Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.
- 8 January 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (1) , e71049
Open AccessPlasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
INTRODUCTION: Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS: Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS: NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION: Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights: Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.
- Top Cited PapersOpen Access
- 3 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4075-4083
Physical activity as a modifiable risk factor in preclinical Alzheimer’s disease
Physical inactivity is a recognized modifiable risk factor for Alzheimer’s disease (AD), yet its relationship with progression of AD pathology in humans remains unclear, limiting the effective translation into prevention trials. Using pedometer-measured step counts in cognitively unimpaired older adults, we demonstrated an association between higher physical activity and slower cognitive and functional decline in individuals with elevated baseline amyloid. Importantly, this beneficial association was not related to lower amyloid burden at baseline or longitudinally. Instead, higher physical activity was associated with slower amyloid-related inferior temporal tau accumulation, which significantly mediated the association with slower cognitive decline. Dose–response analyses further revealed a curvilinear relationship, where the associations with slower tau accumulation and cognitive decline reached a plateau at a moderate level of physical activity (5,001–7,500 steps per day), potentially offering a more approachable goal for older sedentary individuals. Collectively, our findings support targeting physical inactivity as an intervention to modify the trajectory of preclinical AD in future prevention trials, and further suggest that preferentially enrolling sedentary individuals with elevated amyloid may maximize the likelihood of demonstrating a protective effect of physical activity on tau accumulation and cognitive and functional decline in early AD.
- 3 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4075-4083
Top Cited PapersOpen AccessPhysical activity as a modifiable risk factor in preclinical Alzheimer’s disease
Physical inactivity is a recognized modifiable risk factor for Alzheimer’s disease (AD), yet its relationship with progression of AD pathology in humans remains unclear, limiting the effective translation into prevention trials. Using pedometer-measured step counts in cognitively unimpaired older adults, we demonstrated an association between higher physical activity and slower cognitive and functional decline in individuals with elevated baseline amyloid. Importantly, this beneficial association was not related to lower amyloid burden at baseline or longitudinally. Instead, higher physical activity was associated with slower amyloid-related inferior temporal tau accumulation, which significantly mediated the association with slower cognitive decline. Dose–response analyses further revealed a curvilinear relationship, where the associations with slower tau accumulation and cognitive decline reached a plateau at a moderate level of physical activity (5,001–7,500 steps per day), potentially offering a more approachable goal for older sedentary individuals. Collectively, our findings support targeting physical inactivity as an intervention to modify the trajectory of preclinical AD in future prevention trials, and further suggest that preferentially enrolling sedentary individuals with elevated amyloid may maximize the likelihood of demonstrating a protective effect of physical activity on tau accumulation and cognitive and functional decline in early AD.
- Open Access
- 28 April 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (4)
Resistance and resilience to Alzheimer's disease in Down syndrome
Due to the high prevalence of Alzheimer's disease (AD) in adults with Down syndrome (DS), trisomy 21 is now considered a genetic form of AD (DSAD). A better understanding of factors that can prevent or delay AD is vital to improve outcomes for adults with DS. In this narrative review, we apply AD and cognitive aging research frameworks to study resistance and resilience in DSAD. Given the variability in the timing of pathology and symptoms, we discuss the evidence supporting the role of genetic, biological, socio‐behavioral, lifestyle, and environmental factors in resistance and resilience to DSAD. We also consider how co‐occurring health conditions in DS may influence resistance and resilience, and how methods from AD research can be applied to DSAD. Ultimately, this framework aims to guide future research and translate findings into clinical interventions to improve outcomes in DSAD.Highlights: Definitions of resistance and resilience in the genetic form of Alzheimer's disease (DSAD) are proposed for guiding the field. Variability in the timing of AD pathology and symptoms suggests the potential for resistance and resilience mechanisms in DSAD. Genetic, biological, socio‐behavioral, lifestyle, and environmental factors have the potential to build resistance or resilience in DSAD. Future research will require longitudinal and experimental designs, life course approaches, and large cohort studies.
- 28 April 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (4)
Open AccessResistance and resilience to Alzheimer's disease in Down syndrome
Due to the high prevalence of Alzheimer's disease (AD) in adults with Down syndrome (DS), trisomy 21 is now considered a genetic form of AD (DSAD). A better understanding of factors that can prevent or delay AD is vital to improve outcomes for adults with DS. In this narrative review, we apply AD and cognitive aging research frameworks to study resistance and resilience in DSAD. Given the variability in the timing of pathology and symptoms, we discuss the evidence supporting the role of genetic, biological, socio‐behavioral, lifestyle, and environmental factors in resistance and resilience to DSAD. We also consider how co‐occurring health conditions in DS may influence resistance and resilience, and how methods from AD research can be applied to DSAD. Ultimately, this framework aims to guide future research and translate findings into clinical interventions to improve outcomes in DSAD.Highlights: Definitions of resistance and resilience in the genetic form of Alzheimer's disease (DSAD) are proposed for guiding the field. Variability in the timing of AD pathology and symptoms suggests the potential for resistance and resilience mechanisms in DSAD. Genetic, biological, socio‐behavioral, lifestyle, and environmental factors have the potential to build resistance or resilience in DSAD. Future research will require longitudinal and experimental designs, life course approaches, and large cohort studies.
- Open Access
- 19 November 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (12) , 8867-8877
The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1
INTRODUCTION: Though recognized as a potential cause of autosomal dominant Alzheimer's disease, the pathogenicity of many PSEN2 variants remains uncertain. We compared amyloid beta (Aβ) production across all missense PSEN2 variants in the AlzForum database and, when possible, to corresponding PSEN1 variants.METHODS: We expressed 74 PSEN2 variants, 21 of which had known, homologous PSEN1 pathogenic variants with the same amino acid substitution, in HEK293 cells lacking presenilin 1/2. Aβ production was compared to age at symptom onset (AAO) and between PSEN1/2 homologs.RESULTS: Aβ42/40 and Aβ37/42 ratios correlated with AAO across all PSEN2 variants, strongly driven by the subset of PSEN2 variants with PSEN1 homologs. Aβ production across PSEN1/2 homologs was highly correlated. PSEN2 AAO correlated with AAO in PSEN1 homologs but was an average of 18.3 years later.DISCUSSION: The existence of a PSEN1 homolog and patterns of Aβ production are important considerations in assessing the pathogenicity of previously reported and new PSEN2 variants.Highlights: There were associations between the patterns of amyloid beta (Aβ) production across presenilin 2 (PSEN2) variants and age at symptom onset (AAO). PSEN2 variants for which there is a known, corresponding variant in presenilin 1 (PSEN1) are more likely to have abnormal Aβ production patterns that strongly correlate with AAO, compared to those that lack a known PSEN1 counterpart (“non‐homologous PSEN2 variants”). Most PSEN2 variants lacking PSEN1 counterparts had Aβ42/40 ratios close to those of wild‐type PSN2, arguing against their pathogenicity. Homologous PSEN1 and PSEN2 variants had correlated Aβ42/40 and Aβ37/42 ratios, indicating that the corresponding amino acid substitution in each presenilin may have largely similar biochemical effects on γ‐secretase processivity.
- 19 November 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (12) , 8867-8877
Open AccessThe pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1
INTRODUCTION: Though recognized as a potential cause of autosomal dominant Alzheimer's disease, the pathogenicity of many PSEN2 variants remains uncertain. We compared amyloid beta (Aβ) production across all missense PSEN2 variants in the AlzForum database and, when possible, to corresponding PSEN1 variants.METHODS: We expressed 74 PSEN2 variants, 21 of which had known, homologous PSEN1 pathogenic variants with the same amino acid substitution, in HEK293 cells lacking presenilin 1/2. Aβ production was compared to age at symptom onset (AAO) and between PSEN1/2 homologs.RESULTS: Aβ42/40 and Aβ37/42 ratios correlated with AAO across all PSEN2 variants, strongly driven by the subset of PSEN2 variants with PSEN1 homologs. Aβ production across PSEN1/2 homologs was highly correlated. PSEN2 AAO correlated with AAO in PSEN1 homologs but was an average of 18.3 years later.DISCUSSION: The existence of a PSEN1 homolog and patterns of Aβ production are important considerations in assessing the pathogenicity of previously reported and new PSEN2 variants.Highlights: There were associations between the patterns of amyloid beta (Aβ) production across presenilin 2 (PSEN2) variants and age at symptom onset (AAO). PSEN2 variants for which there is a known, corresponding variant in presenilin 1 (PSEN1) are more likely to have abnormal Aβ production patterns that strongly correlate with AAO, compared to those that lack a known PSEN1 counterpart (“non‐homologous PSEN2 variants”). Most PSEN2 variants lacking PSEN1 counterparts had Aβ42/40 ratios close to those of wild‐type PSN2, arguing against their pathogenicity. Homologous PSEN1 and PSEN2 variants had correlated Aβ42/40 and Aβ37/42 ratios, indicating that the corresponding amino acid substitution in each presenilin may have largely similar biochemical effects on γ‐secretase processivity.
- Open Access
- 18 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease
Disease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes. Here, we update and complement previous findings from the Dominantly Inherited Alzheimer Network Observational Study by using matched cross-sectional and longitudinal cerebrospinal fluid (CSF) and plasma samples from 567 individuals, allowing timely comparative analyses of CSF and blood trajectories across the entire disease spectrum. CSF and plasma trajectories were similar at presymptomatic stages, discriminating mutation carriers from non-carrier controls 10-20 years before the estimated onset of clinical symptoms, depending on the statistical model used. However, after symptom onset the rate of change in CSF NfL continued to increase steadily, whereas the rate of change in plasma NfL leveled off. Both plasma and CSF NfL changes were associated with grey-matter atrophy, but not with Aβ-PET changes, supporting a temporal decoupling of Aβ deposition and neurodegeneration. These observations support NfL in both CSF and blood as an early marker of neurodegeneration but suggest that NfL measured in the CSF may be better suited for monitoring clinical trial outcomes in symptomatic AD patients.
- 18 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Open AccessComparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease
Disease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes. Here, we update and complement previous findings from the Dominantly Inherited Alzheimer Network Observational Study by using matched cross-sectional and longitudinal cerebrospinal fluid (CSF) and plasma samples from 567 individuals, allowing timely comparative analyses of CSF and blood trajectories across the entire disease spectrum. CSF and plasma trajectories were similar at presymptomatic stages, discriminating mutation carriers from non-carrier controls 10-20 years before the estimated onset of clinical symptoms, depending on the statistical model used. However, after symptom onset the rate of change in CSF NfL continued to increase steadily, whereas the rate of change in plasma NfL leveled off. Both plasma and CSF NfL changes were associated with grey-matter atrophy, but not with Aβ-PET changes, supporting a temporal decoupling of Aβ deposition and neurodegeneration. These observations support NfL in both CSF and blood as an early marker of neurodegeneration but suggest that NfL measured in the CSF may be better suited for monitoring clinical trial outcomes in symptomatic AD patients.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S4)
Relation of modifiable lifestyle and mood factors to subjective cognitive concerns among participants and their study partners in the A4 screen data
Background: Subjective cognitive decline (SCD) is associated with future cognitive decline, elevated amyloid levels, and non‐specific variables, including mood. Participants often endorse higher cognitive concerns than their study partners (SPs), raising the possibility that participant complaints reflect multiple factors, including mood, lifestyle variables, and amyloid status. To determine the predictive value of modifiable factors, we examined the relation between SCD, lifestyle habits, amyloid, and mood among cognitively unimpaired older adults from a multi‐site secondary prevention trial (A4 screen data).Method: Participants were 6943 individuals from A4 assessed pre‐randomization [mean(SD): age = 71.6(4.9), education = 16.4(3.0); 58% women, 95% non‐Hispanic or Latino, 90% white)]. Using descriptive analyses and linear regression models, we examined whether amyloid status (amyloid+: n = 1329/4492) and self‐reported mood (Geriatric Depression Scale [GDS]) or lifestyle habits (exercise, sleep) predicted subjective cognitive concerns (CFI; participant‐ and SP‐reported).Result: Participants endorsed healthy lifestyle habits (mean hours of aerobic exercise/week = 2.9; mean hours of sleep/night = 7.1), minimal mood symptoms (mean GDS = 1.1), and higher cognitive concerns than SPs (t(5996) = ‐25.08, p<.001). Lower mood (t = 29.49, p<.001), older age (t = 5.75, p<.001), and lower education (t = ‐3.92, p<.001) predicted participant concerns on the CFI, with additive predictive value of lower self‐reported exercise (t = ‐2.90, p = .004) and sleep duration (t = ‐2.12, p = .035); however, only lower participant‐reported mood (t = 12.90, p<.001) and older participant age (t = 6.54, p<.001) predicted SP concerns. Adding amyloid to the model in a subset, all predictors for participant concerns remained except sleep, while only amyloid status (t = 4.59, p<.001), lower mood (t = 11.53, p<.001), and older age (t = 4.72, p<.001) predicted SP concerns.Conclusion: Cognitively unimpaired participants endorsed higher cognitive concerns on the CFI compared to their SPs. Participant concerns were associated with multiple predictors (age, education, mood, amyloid status, exercise, sleep), while SP concerns were only associated with age, mood, and amyloid status. Participants may be more aware of early changes and endorse concerns reflecting various factors, including personal lifestyle habits, while SP report may be more specific to cognitive changes due to age and amyloid burden. These findings expand understanding of how various factors (e.g., biomarkers, mood, lifestyle habits) may contribute differently to participant and SP cognitive concerns, which may inform research recruitment and clinical care.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S4)
Open AccessRelation of modifiable lifestyle and mood factors to subjective cognitive concerns among participants and their study partners in the A4 screen data
Background: Subjective cognitive decline (SCD) is associated with future cognitive decline, elevated amyloid levels, and non‐specific variables, including mood. Participants often endorse higher cognitive concerns than their study partners (SPs), raising the possibility that participant complaints reflect multiple factors, including mood, lifestyle variables, and amyloid status. To determine the predictive value of modifiable factors, we examined the relation between SCD, lifestyle habits, amyloid, and mood among cognitively unimpaired older adults from a multi‐site secondary prevention trial (A4 screen data).Method: Participants were 6943 individuals from A4 assessed pre‐randomization [mean(SD): age = 71.6(4.9), education = 16.4(3.0); 58% women, 95% non‐Hispanic or Latino, 90% white)]. Using descriptive analyses and linear regression models, we examined whether amyloid status (amyloid+: n = 1329/4492) and self‐reported mood (Geriatric Depression Scale [GDS]) or lifestyle habits (exercise, sleep) predicted subjective cognitive concerns (CFI; participant‐ and SP‐reported).Result: Participants endorsed healthy lifestyle habits (mean hours of aerobic exercise/week = 2.9; mean hours of sleep/night = 7.1), minimal mood symptoms (mean GDS = 1.1), and higher cognitive concerns than SPs (t(5996) = ‐25.08, p<.001). Lower mood (t = 29.49, p<.001), older age (t = 5.75, p<.001), and lower education (t = ‐3.92, p<.001) predicted participant concerns on the CFI, with additive predictive value of lower self‐reported exercise (t = ‐2.90, p = .004) and sleep duration (t = ‐2.12, p = .035); however, only lower participant‐reported mood (t = 12.90, p<.001) and older participant age (t = 6.54, p<.001) predicted SP concerns. Adding amyloid to the model in a subset, all predictors for participant concerns remained except sleep, while only amyloid status (t = 4.59, p<.001), lower mood (t = 11.53, p<.001), and older age (t = 4.72, p<.001) predicted SP concerns.Conclusion: Cognitively unimpaired participants endorsed higher cognitive concerns on the CFI compared to their SPs. Participant concerns were associated with multiple predictors (age, education, mood, amyloid status, exercise, sleep), while SP concerns were only associated with age, mood, and amyloid status. Participants may be more aware of early changes and endorse concerns reflecting various factors, including personal lifestyle habits, while SP report may be more specific to cognitive changes due to age and amyloid burden. These findings expand understanding of how various factors (e.g., biomarkers, mood, lifestyle habits) may contribute differently to participant and SP cognitive concerns, which may inform research recruitment and clinical care.
- Open Access
- 8 June 2023
- Published by Wiley in Aging Cell
- Vol. 22 (8) , e13871
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.
- 8 June 2023
- Published by Wiley in Aging Cell
- Vol. 22 (8) , e13871
Open AccessLocation of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.